Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Ítems similars

• Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone
  per: Riswold, Kayla, et al.
  Publicat: (2018)
• Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
  per: Ko, Jung-Woo, et al.
  Publicat: (2020)
• Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System
  per: Cheng, Carmen, et al.
  Publicat: (2016)
• Comparison of Brand versus Generic Antiepileptic Drug Adverse Event Reporting Rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
  per: Rahman, Md. Motiur, et al.
  Publicat: (2017)
• Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  per: Raschi, Emanuel, et al.
  Publicat: (2019)